Europe
A dual treatment approach consisting of gemcitabine combined with AB Science’s masitinib was associated with significant increases in survival among patients with pancreatic cancer and pain.
The four promising treatments showed no effect on reducing mortality in ongoing Solidarity Trial.
Governments across the globe have flexed their financial muscles to secure promises of as many doses of COVID-19 vaccines as possible when they become available.
Biopharma companies who have COVID-19 vaccines in development, have astonished skeptics by the speed with which they have developed vaccines.. But now comes an even more daunting challenge—scaling up manufacturing and distribution.
Nucleic-acid-based assays are the gold standard for detecting the presence of the SARS-CoV-2 virus, but they eventually will be replaced with simpler and more advanced techniques, such as CRISPR-Cas, LAMP, and other faster and less-expensive methods.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Merck KGaA and Artios Pharma Limited announced today that they have entered a strategic collaboration agreement to discover and develop multiple precision oncology drugs over the course of the next three years.
Yesterday, the United Kingdom’s MHRA granted temporary authorization for emergency use to Pfizer and BioNTech for their COVID-19 mRNA vaccine. It didn’t take long for the decision to generate criticism and questions.
The U.S. Food and Drug Administration has given Emergency Use Authorization (EUA) to a COVID-19 test developed by Roche that measures antibodies within the blood.
PRESS RELEASES